United Kingdom· GB-APID-42875211000001106
Rystiggo 280mg/2ml solution for injection vials
A rozanolixizumab product containing rozanolixizumab, registered in United Kingdom by UCB Pharma Ltd. The same ATC class is registered in 7 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Rozanolixizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC L04AL02 (rozanolixizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 5 of them publish a price we can compare per daily dose
Rozanolixizumab · ATC L04AL02
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Rozanolixizumab
- Manufacturer
- UCB Pharma Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AL02
- ATC class
- Rozanolixizumab
- Defined daily dose
- 80 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05413787221912
- gtin5413787221912
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rozanolixizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRystiggo 140 mg/mlUCB Pharma
- CzechiaRYSTIGGOUCB Pharma SA, Brusel
- United StatesRYSTIGGOUCB, Inc.
- Japanロザノリキシズマブ（遺伝子組換え）ユーシービージャパン
- SwitzerlandRystiggo 280 mg/2 ml, solution injectableUCB-Pharma SA
- IrelandRystiggo 140 mg/ml solution for injectionUCB Pharma S.A.
- IcelandRystiggoUCB Pharma S.A.*
- NetherlandsRystiggo 140 mg/ml oplossing voor injectieUCB Pharma S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rystiggo
- Liechtenstein · Rystiggo
- Norway · Rystiggo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/80471d08-f43e-41c7-a742-e1c03e65509c GET /v1/drugs/80471d08-f43e-41c7-a742-e1c03e65509c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42875211000001106",
"desc": "Rystiggo 280mg/2ml solution for injection vials (UCB Pharma Ltd)",
"form": "Solution for infusion",
"vpid": "42880411000001108",
"source": "dmd",
"vtm_id": "42876711000001107",
"strength": "140 mg",
"substance": "Rozanolixizumab",
"ingredient": "Rozanolixizumab",
"supplier_code": "2089701000001105"
}See everything about rozanolixizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.